obesity-995x60.png
FEATURED ARTICLES
Designing Trials For Disease Modification: Cereno Scientific's Approach To Pulmonary Arterial Hypertension
Cereno Scientific’s Rahul Agrawal discusses the scientific and strategic rationale behind extending the company’s Phase 2b study duration and how the company incorporated regulator and patient input.
-
The FDA Could Clear The Path For A Strep A Vaccine. Why Hasn't It?
Strep A kills around 500,000 people each year, and a vaccine would change this and is within reach. Yet, no strep A vaccine is currently in Phase 3. 1Day Sooner's Josh Morrison explains why and shares how FDA could make Strep A vaccines a reality.
-
Anthropic's Stainless Acquisition: What It Means For Clinical Trials
As AI models become interchangeable, value is shifting to the orchestration layer that connects tools, workflows, and governance—making flexibility, interoperability, and auditability critical.
-
How Acquiring Sponsors Can Keep Post-Acquisition Clinical Operations Running Smoothly
When acquiring another company, the acquiring sponsor must preserve operational continuity across active trials while integrating new assets, teams, technologies, vendors, and decision structures. Leila Cupersmith explains how.